Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) Net Income towards Common Stockholders (2016 - 2025)

Aptevo Therapeutics' Net Income towards Common Stockholders history spans 10 years, with the latest figure at -$9.1 million for Q3 2025.

  • For Q3 2025, Net Income towards Common Stockholders changed N/A year-over-year to -$9.1 million; the TTM value through Sep 2025 reached -$21.8 million, down 7538.57%, while the annual FY2023 figure was $1.2 million, 22.31% up from the prior year.
  • Net Income towards Common Stockholders for Q3 2025 was -$9.1 million at Aptevo Therapeutics, down from -$6.2 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $946000.0 in Q1 2023 and bottomed at -$9.1 million in Q3 2025.
  • The 4-year median for Net Income towards Common Stockholders is $165000.0 (2022), against an average of -$1.4 million.
  • The largest annual shift saw Net Income towards Common Stockholders plummeted 96.79% in 2021 before it skyrocketed 431.46% in 2023.
  • A 4-year view of Net Income towards Common Stockholders shows it stood at $325000.0 in 2021, then skyrocketed by 60.31% to $521000.0 in 2022, then crashed by 43.76% to $293000.0 in 2023, then plummeted by 3202.05% to -$9.1 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Net Income towards Common Stockholders are -$9.1 million (Q3 2025), -$6.2 million (Q2 2025), and -$6.5 million (Q1 2025).